CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
TG4010 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02823990
NCT02823990Phase 2Completed
CompareCT.gov

Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Megan Daly, MD·interventional·Posted Jul 6, 2016·Updated Nov 10, 2025

In Brief

A Phase 2 clinical trial evaluating TG4010 and Nivolumab for Recurrent Non-Small Cell Lung Carcinoma and 5 related conditions. Completed, enrolled 13 participants across 4 sites.

Detailed Summary

This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab, interfere with the ability of tumor cells to grow and spread. Giving TG4010 and nivolumab together may work better in previously treated patients with non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Transgene, Bristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 6, 2016
Enrollment StartDec 14, 2016
Primary CompletionFeb 24, 2021
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.0 years ago

Interventions

TG4010biological

Given SC

Nivolumabbiological

Given IV